

ACCORD 2 Newsletter


ACCORD – a national Phase 2, CMO prioritised study funded by UKRI and supported by the NIHR to develop the next generation of drugs for COVID-19.

The drugs currently in trial are:

- **Bemcentinib** – AXL inhibitor which may prevent viral infection and lung inflammation
- **Acalabrutinib** – a Bruton's tyrosine kinase (BTK) inhibitor
- **MEDI3506** – an anti-IL-33 monoclonal antibody
- **Zilucoplan** – a complement C5 inhibitor that could block severe inflammatory responses

Active ACCORD Sites

A map of the 32 ACCORD UK sites are, larger dots for grouped sites



We wish you every success with recruitment!

The four national early phase platform trials (ACCORD, CATALYST, DEFINE and TACTIC) have formally agreed to work as an alliance to accelerate patient recruitment, data analysis and delivery of therapeutic drugs for COVID-19 patients.

“We will jointly review drugs and sites in a transparent manner, communicate our collaborative and common purpose to all sites that we approach, share our data at appropriate milestones, and support each other's efforts. The alliance will offer UK-wide early phase trials capability for the current COVID-19 and preparedness for future waves.”

Recruitment Figures so far:

Arm 002 Bemcentinib -	3
Arm 003 Acalabrutinib -	4
Arm 004 MEDI3506 -	4
Arm 006 Zilucoplan -	4



Remdesivir Update

MHRA- Early Access to Medicines Scheme (EAMS) gave approval for use of Remdesivir for treatment of COVID-19 in adults and adolescents.

The ACCORD programme team has reviewed potential effects on each sub-protocol and concurrent use of Remdesivir is permitted with all ACCORD drugs in trial. Data on administration will be collected in the updated eCRF.

Dexamethasone Update

Following the recent headline results from the RECOVERY trial which report an improvement in mortality with dexamethasone treatment in hypoxic and ventilated COVID 19 patients, the CMO has recommended its use in these patient groups.

Following review with the ACCORD drug sponsors – it has been agreed that use of dexamethasone is permitted in all arms of the current ACCORD programme with appropriate clinical oversight and capture of dexamethasone prescription in the updated eCRF.

A new master protocol and subsequent amendments to the arms will go live this week.